Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

462.90 -0.09 (-0.02%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

69 70 Next >

Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts? ↗

November 04, 2024

VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock faces bearish trend.

Via Benzinga

Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers ↗

November 02, 2024

It won't be able to be profitable without hitting its targets for both of these figures.

Via The Motley Fool

As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report ↗

November 01, 2024

Amid the election, and a Fed rate vote, earnings season roars ahead.

Via Investor's Business Daily

Topics Economy Stocks

Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies' ↗

October 31, 2024

Mad Money's Jim Cramer recommends buying T. Rowe Price Group. "I think it's such a great company," he added.

Via Benzinga

Looking Into Vertex Pharmaceuticals's Recent Short Interest ↗

October 21, 2024

Via Benzinga

Market Whales and Their Recent Bets on VRTX Options ↗

October 18, 2024

Via Benzinga

What Analysts Are Saying About Vertex Pharmaceuticals Stock ↗

October 01, 2024

Via Benzinga

Vertex to Participate in Upcoming November Investor Conferences

October 29, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years ↗

October 28, 2024

Via Benzinga

These 10 Stocks Were The Best S&P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself? ↗

October 28, 2024

A look back at the top 10 S&P 500 performing stocks in 2017 under Donald Trump's first year as president and what it could mean for his re-election efforts.

Via Benzinga

Topics Government Stocks

12 High-Growth Stocks That Could Deliver Parabolic Returns ↗

October 28, 2024

These 12 innovative companies could deliver exponential returns over the next quarter century.

Via The Motley Fool

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

October 25, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

The Smartest Growth Stock to Buy With $500 Right Now ↗

October 25, 2024

This stock might not be available for under $500 for long.

Via The Motley Fool

Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits ↗

October 24, 2024

Its latest report of clinical data suggests it has a winner on its hands.

Via The Motley Fool

Why We Buy Stocks ↗

October 21, 2024

Is fear of missing out (FOMO) controlling your portfolio?

Via The Motley Fool

Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030 ↗

October 19, 2024

There's no need to change a winning formula.

Via The Motley Fool

Topics Stocks

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting

October 18, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (19 Ratings) ↗

October 17, 2024

Via Benzinga

Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today ↗

October 16, 2024

Via Benzinga

Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever ↗

October 13, 2024

These profitable companies are facing long-term growth runways.

Via The Motley Fool

3 No-Brainer Growth Stocks to Buy in October ↗

October 13, 2024

These stocks look like slam-dunk picks for growth investors.

Via The Motley Fool

Vertex to Announce Third Quarter 2024 Financial Results on November 4th

October 10, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

2 Biotech Stocks to Buy Hand Over Fist in October ↗

October 09, 2024

These longtime leading biotech stocks still have plenty of upside ahead.

Via The Motley Fool

Cathie Wood's Ark Invest Trades: Bets $14M On Amazon Shares — Dumps Robinhood Stock Worth $36M, Embraces Coinbase And Meta ↗

October 08, 2024

Cathie Wood's Ark Invest made significant trades in Amazon.com Inc (NASDAQ: AMZN), Robinhood Markets Inc (NASDAQ: HOOD), and Coinbase Global Inc (NASDAQ: COIN) on Tuesday Oct 8, 2024.

Via Benzinga

S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion' ↗

October 07, 2024

Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors.

Via Benzinga

Topics Artificial Intelligence Stocks

Insider Trades: How To Find The Top Stocks ↗

October 04, 2024

There are dozens of insider trades going on every week. Here are 5 insider stock buys that stand out.

Via Talk Markets

3 Top Stocks That Could Still Rocket Higher in 2024 ↗

October 04, 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

Via The Motley Fool

2 Superior Growth Stocks That Are Screaming Buys Right Now ↗

October 04, 2024

These companies have plenty of growth runway left.

Via The Motley Fool

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗

September 26, 2024

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Via Investor's Business Daily

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.